Marta Figueiredo, PhD,  managing science editor—

Multiple sclerosis (MS) patients with fatigue have significantly lower levels of amyloid precursor protein (APP) — a molecule involved in nerve cell function — in the cerebrospinal fluid (CSF) relative both to those without this common symptom and healthy people, a study shows. The CSF is the liquid…

Biogen has entered a licensing agreement to develop and potentially commercialize MedRhythms‘ investigational music-based digital therapy, MR-004, designed to help make walking easier for people with multiple sclerosis (MS). The partnership combines Biogen’s leadership and expertise in MS with MedRhythms’ digital therapeutics platform that uses sensors, algorithms, and music…

Reports of psoriasis — an autoimmune skin disease that shares some biological processes with multiple sclerosis (MS) — are disproportionally high among MS patients on therapies that deplete B-cells, according to a U.S. study based on patient adverse event data. Conversely, patients on Tysabri (natalizumab), glatiramer acetate (sold…

The uncertainties that accompany multiple sclerosis (MS) are among the biggest challenges faced by people with the disease, with two-thirds of patients in a recent survey saying “they’re scared for the future” because of such unknowns, the MS Society, which conducted the U.K. survey, reports. “We may all think the…

Multiple sclerosis (MS) affects all aspects of life, from physical and mental health to relationships, and from work and finances to hobbies and holidays, according to results from an online survey conducted by the U.K.’s MS Trust. Most respondents said they wanted more support to manage their fatigue, improve…

Plegridy (peginterferon beta-1a), an approved treatment for relapsing multiple sclerosis (MS), is detected at minimal concentrations in the breast milk of patients using the therapy postpartum, a small study showed. This is in line with label updates on Plegridy and other interferon beta therapies in Europe and…

Physician-researchers at Cedars-Sinai Medical Center, in California, are developing brain and eye imaging techniques to improve the diagnosis and management of multiple sclerosis (MS). MS is characterized by the progressive loss of myelin, the fatty protective sheath around nerve fibers, in the brain and spinal cord due to abnormal…

Atara Biotherapeutics plans to launch two Phase 3 clinical trials of its investigational immunotherapy ATA188 in people with non-active, progressive forms of multiple sclerosis (MS). Whether efforts for these trials will go forward, however, depends on positive results from an interim analysis of the Phase 2 portion of the…

A Phase 1/2 clinical trial evaluating Imcyse’s experimental therapy IMCY-0141 in people with relapsing-remitting multiple sclerosis (RRMS) has dosed its first patient. The trial, called IMCY-MS-001, is expected to enroll nearly 150 adults with RRMS; sites were not disclosed in a release by the Belgium-based company. Interim results may be available…

The Australian government has announced that a record AU$18 million (about $13.5 million) from the Medical Research Future Fund will be used to support research into multiple sclerosis (MS) as part of its 2022–23 budget. Grant opportunities will focus on increasing access to clinical trials and speeding the development of effective…

Based on findings from the first two secondary progressive multiple sclerosis (SPMS) patients given foralumab nasal spray, an experimental therapy, the U.S. Food and Drug Administration (FDA) has approved starting treatment in up to eight other patients under a special access program. Those enrolled in this intermediate-size expanded access…

Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods, has helped to advance research into a blood biomarker expected to predict future disease activity in multiple sclerosis (MS) patients. Specifically, Quanterix‘s ultra-sensitive technology allowed an international team…

Long-term treatment with evobrutinib safely and effectively reduces the rate of relapses in adults with relapsing forms of multiple sclerosis (MS), according to 2.5 years of data from a Phase 2 extension study. These findings — supporting evobrutinib’s therapeutic potential in relapsing MS — were shared in an…

The National Multiple Sclerosis Society (NMSS) has detailed its Pathways to Cures Roadmap and potential ways of addressing gaps and advancing each of the pathways, with a final goal of finding a cure for multiple sclerosis (MS) in all its forms. Details were in the report, “…

Higher doses of temelimab were generally safe and resulted in beneficial trends on key neurodegeneration markers in adults with relapsing forms of multiple sclerosis (MS) who already were on rituximab treatment, according to top-line data from the ProTEct-MS Phase 2 clinical trial. While the study’s small size…

Six months of treatment with foralumab, an experimental nasal spray, safely and effectively improved motor and cognitive function while easing immune activation and inflammatory responses in a person with secondary progressive multiple sclerosis (SPMS), Tiziana Life Sciences, the therapy’s developer, announced. The patient — the first with MS to…

Cionic has received authorization from the U.S. Food and Drug Administration (FDA) to market its lightweight, leg-worn Neural Sleeve to improve walking in people with multiple sclerosis (MS) and other conditions that affect mobility. The decision comes four months after the company submitted the device — the first to…

The number of nurses in the U.K. with a specialty in multiple sclerosis (MS) care rose significantly between 2018 and 2021, but these specialists on average carry a patient caseload that’s 50% higher than recommended, as a pronounced rise in MS cases was also noted, the MS Trust reports.

Administering the stem cell therapy NG-01 — designed to have neuroprotective and neuro-regenerative properties — directly into the spinal canal can significantly reduce the levels of neurofilament light chain (NfL), a neuronal damage biomarker, in people with active, progressive forms of multiple sclerosis (MS). These are the new…

Masitinib, AB Science’s experimental oral therapy, significantly slows disability progression in adults with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS), according to final data from the AB07002 Phase 2b/3 clinical trial. These findings, indicating that the trial met its main goal, support…

  Synaptogenix announced plans to advance bryostatin-1, its lead candidate, into clinical trials for multiple sclerosis (MS), marking the third neurological disease the small molecule therapy is being developed to potentially treat. “Multiple sclerosis joins Alzheimer’s disease (“AD”) and Fragile X syndrome as our third indication with potential clinical…

Lower-than-normal volumes of certain brain regions at disease onset — indicating shrinkage, or atrophy, in those regions — are significantly associated with current and future fatigue severity in people with multiple sclerosis (MS), a study in Germany shows. Some of these regions also were found to be central brain…

The label of Copaxone (glatiramer acetate) — an approved therapy for relapsing forms of multiple sclerosis (MS) — has been updated in Europe to no longer contain a warning against its use during breastfeeding. The label update follows a review by European Union health authorities of non-clinical and clinical evidence submitted…

Almost half of multiple sclerosis (MS) patients show reduced bone density (osteopenia) and about 17% have osteoporosis, a progressive disease characterized by weak bones that are prone to fractures, a review study of data covering almost 14,000 patients reported. These findings suggest that people with MS should be monitored…

The Swedish Medical Products Agency has approved AB Science’s request to launch in the country a confirmatory Phase 3 clinical trial of its lead candidate masitinib in adults with primary progressive multiple sclerosis (PPMS) and nonactive secondary progressive MS (SPMS). The decision comes on the heels of a similar authorization by the…

KAT7, an enzyme known to regulate gene activity, is essential for the process of teaching immune T-cells to correctly identify the body’s molecules and cells as ‘self’ — a process that goes awry in multiple sclerosis (MS) and other autoimmune diseases. This enzyme is also critical for training T-cells…

Nearly a third of multiple sclerosis (MS) patients with COVID-19 experience symptoms that last at least one month, according to a review of of more than 550 infected MS patients in the U.K. who did not need to be hospitalized. This study’s rate is higher than that reported for the…

ANI Pharmaceuticals has announced the full U.S. commercial availability of Cortrophin Gel (repository corticotropin injection), an injectable therapy approved for managing acute relapses in people with multiple sclerosis (MS) and other autoimmune disorders. “Patients with certain chronic autoimmune conditions often need additional treatment options,” Mary Pao Seideman, MD,…

Multiple sclerosis (MS) patients with weak immune responses to COVID-19 vaccines are more likely to respond successfully to the booster shot if they are receiving an anti-CD20 therapy compared with those on Gilenya (fingolimod), according to a small study in Norway. These early findings suggest that booster shots…

The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeutics’ experimental oral therapy IMU-838 (vidofludimus calcium) in adults with relapsing-remitting multiple sclerosis (RRMS), has enrolled its first patient. The milestone, announced in an email to Multiple Sclerosis News Today, follows the recruitment of the first RRMS patient in…